1992•Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)Requires access

EFFICACITE DE LA FLUVOXAMINE DANS LES CAS DE DEPRESSION GRAVE

Julien Mendlewicz

Open publisher page 0 citations

Abstract

The therapeutic efficacy of fluvoxamine has been demonstrated in large numbers of patients participating in comparative double-blind-placebo-controlled studies using imipramine as the active reference compound. Overall, patients treated with fluvoxamine for 4 to 6 weeks had significant amelioration of their depression compared with placebo-treated patients. More importantly, the response rate in patients with severe depression was greater than in patients with mild or moderate depression. However, several investigators have observed high placebo response rates and in some studies there has been a similar response rate to imipramine and placebo treatment. While the high-placebo response rate may have resulted from methodological problems, the issue does raise some questions that can only be resolved by further investigation.

About this research paper

What this paper is about

The therapeutic efficacy of fluvoxamine has been demonstrated in large numbers of patients participating in comparative double-blind-placebo-controlled studies using imipramine as the active reference compound. Overall, patients treated with fluvoxamine for 4 to 6 weeks had significant amelioration of their depression compared with placebo-treated patients. More importantly, the response rate in patients with severe depression was greater than in patients with mild or moderate depression. However, several investigators have observed high placebo response rates and in some studies there has been a similar response rate to imipramine and placebo treatment. While the high-placebo response rate may have resulted from methodological problems, the issue does raise some questions that can only be resolved by further investigation.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The therapeutic efficacy of fluvoxamine has been demonstrated in large numbers of patients participating in comparative double-blind-placebo-controlled studies using imipramine as the active reference compound. Overall, patients treated with fluvoxamine for 4 to 6 weeks had significant amelioration of their depression compared with placebo-treated patients. More importantly, the response rate in patients with severe depression was greater than in patients with mild or moderate depression. However, several investigators have observed high placebo response rates and in some studies there has been a similar response rate to imipramine and placebo treatment. While the high-placebo response rate may have resulted from methodological problems, the issue does raise some questions that can only be resolved by further investigation.

Key concepts: Fluvoxamine, Placebo, Placebo response, Imipramine, Depression (economics), Medicine, Psychology, Anesthesia

Back to paper searchBrowse research topicsOriginal source
EFFICACITE DE LA FLUVOXAMINE DANS LES CAS DE DEPRESSION GRAVE — Research Paper | ScholarLens